Barresi & Mitchell Od's Optometrist Medicare: Not Enrolled in Medicare Practice Location: 12 W Main St, Fort Kent, ME 04743 Phone: 207-834-3124 Fax: 207-834-3127 |
Dr. David A Mitchell, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 12 W Main St, Fort Kent, ME 04743 Phone: 207-834-3124 Fax: 207-834-3127 |
Dr. Amber Christine Caron, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 12 Bolduc Ave, Fort Kent, ME 04743 Phone: 207-834-3124 Fax: 207-834-3127 |
Timothy D Rioux Optometrist Medicare: Not Enrolled in Medicare Practice Location: 29 Meadow Lane, Fort Kent, ME 04743 Phone: 207-834-3333 Fax: 207-834-6095 |
Timothy Rioux, Od Pa Optometrist Medicare: Medicare Enrolled Practice Location: 29 Meadow Lane, Fort Kent, ME 04743 Phone: 207-834-3333 Fax: 207-834-6095 |
Dr. Brent Stoliker, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 29 Meadow Ln, Fort Kent, ME 04743 Phone: 207-834-3333 Fax: 207-834-6095 |
Dr. Timothy David Rioux, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 29 Meadow Ln, Fort Kent, ME 04743 Phone: 207-834-3333 Fax: 207-834-6095 |
News Archive
An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.
Zebrafish are the new fruit flies.
A brain circuit that underlies feelings of stress and anxiety shows promise as a new therapeutic target for alcoholism, according to new studies by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH).
The Department of Defense today issued an interim final rule designating pharmacies as providers for H1N1, seasonal flu and pneumonia vaccinations under its TRICARE program.
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced the closing of its previously announced sale of $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. The investor has elected to convert all of its shares of Series 2 Preferred Stock and to receive the 18,853,103 shares of the Company's common stock issuable upon such conversion at the closing.
› Verified 7 days ago